Healthcare Global Enterprises Q4 FY26 Update

Healthcare Global Enterprises (HCG) delivered Q4FY26 results broadly in line with expectations, showing 11.5% revenue growth and margin expansion. Goldman Sachs maintains its 'Not Rated' status due to its role as a financial advisor but has slightly lowered forward EBITDA estimates.

Key Takeaways

• 1.Healthcare Global Enterprises reported Q4FY26 revenue and EBITDA growth of 11.5% and 18% year-over-year, respectively, meeting consensus expectations.
• 2.EBITDA margins improved by 111 basis points year-over-year to 19.2% due to improved operating leverage.
• 3.Goldman Sachs has lowered its FY26-28E EBITDA estimates by up to 2% based on the Q4 results and management outlook.

Table of Contents

• Result update
• Estimate changes
• Disclosure Appendix
• GS Factor Profile
• M&A Rank
• Quantum
• Disclosures
• Price target and rating history chart(s)
• Target price history table(s)
• Regulatory disclosures
• Ratings, coverage universe and related definitions
• Global product; distributing entities
• General disclosures

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial